KR20240033168A - 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 - Google Patents

항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Download PDF

Info

Publication number
KR20240033168A
KR20240033168A KR1020247007023A KR20247007023A KR20240033168A KR 20240033168 A KR20240033168 A KR 20240033168A KR 1020247007023 A KR1020247007023 A KR 1020247007023A KR 20247007023 A KR20247007023 A KR 20247007023A KR 20240033168 A KR20240033168 A KR 20240033168A
Authority
KR
South Korea
Prior art keywords
seq
bdca2
concentration
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247007023A
Other languages
English (en)
Korean (ko)
Inventor
마크 알. 에이치. 크렙스
데이빗 다이
샨타누 슐레
다니아 라바
데이빗 마르틴
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Priority to KR1020247035142A priority Critical patent/KR20240159012A/ko
Publication of KR20240033168A publication Critical patent/KR20240033168A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247007023A 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Ceased KR20240033168A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247035142A KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
KR1020227005469A KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005469A Division KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035142A Division KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Publications (1)

Publication Number Publication Date
KR20240033168A true KR20240033168A (ko) 2024-03-12

Family

ID=58672794

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020247007023A Ceased KR20240033168A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020187034043A Active KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020227005469A Ceased KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187034043A Active KR102366547B1 (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020247035142A Ceased KR20240159012A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020227005469A Ceased KR20220028150A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
KR1020257018429A Pending KR20250088784A (ko) 2016-04-28 2017-04-27 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법

Country Status (14)

Country Link
US (2) US20190284281A1 (https=)
EP (1) EP3448425A1 (https=)
JP (3) JP7045327B2 (https=)
KR (5) KR20240033168A (https=)
CN (2) CN109475623B (https=)
AU (2) AU2017258191B2 (https=)
CA (1) CA3022116A1 (https=)
CO (1) CO2018012506A2 (https=)
EA (1) EA201892443A1 (https=)
IL (2) IL262514B2 (https=)
MA (1) MA44763A (https=)
MX (3) MX2018012945A (https=)
PH (1) PH12018502278A1 (https=)
WO (1) WO2017189827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CA3203971A1 (en) 2020-12-03 2022-06-09 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
EP4385525A1 (en) 2021-08-09 2024-06-19 Inventera Inc. Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
CN120475994A (zh) * 2022-12-28 2025-08-12 映恩生物科技(上海)有限公司 抗bdca2抗体-药物偶联物及其用途
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
CN111961134B (zh) * 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途

Also Published As

Publication number Publication date
CA3022116A1 (en) 2017-11-02
IL262514B1 (en) 2025-08-01
MA44763A (fr) 2019-03-06
KR20190002563A (ko) 2019-01-08
EA201892443A1 (ru) 2019-04-30
IL321561A (en) 2025-08-01
US20250289895A1 (en) 2025-09-18
US20190284281A1 (en) 2019-09-19
JP7045327B2 (ja) 2022-03-31
MX2018012945A (es) 2019-03-06
IL262514A (en) 2018-12-31
KR20250088784A (ko) 2025-06-17
KR20240159012A (ko) 2024-11-05
NZ747504A (en) 2025-08-29
AU2024203240A1 (en) 2024-06-13
CN116850282A (zh) 2023-10-10
KR102366547B1 (ko) 2022-02-23
JP2022084782A (ja) 2022-06-07
IL262514B2 (en) 2025-12-01
CN109475623A (zh) 2019-03-15
CN109475623B (zh) 2023-05-26
KR20220028150A (ko) 2022-03-08
EP3448425A1 (en) 2019-03-06
AU2017258191A1 (en) 2018-11-15
JP2024038308A (ja) 2024-03-19
CO2018012506A2 (es) 2018-12-14
PH12018502278A1 (en) 2019-09-09
WO2017189827A1 (en) 2017-11-02
MX2025000037A (es) 2025-02-10
MX2023008075A (es) 2023-07-18
AU2017258191B2 (en) 2024-06-13
BR112018072125A2 (pt) 2019-03-19
NZ787392A (en) 2025-08-29
JP2019520316A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
US20250289895A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
EP4257199A2 (en) Humanized anti-human-pd-1 antibody
EP3351560B1 (en) Medical use of high affinity human antibodies to human il-4 receptor
US20220056135A1 (en) Bifunctional anti-pd-1/sirpa molecule
KR20220047826A (ko) 고 농도의 항-c5 제형
CN111808190A (zh) 结合pd-1的抗体
KR20180039172A (ko) 루푸스 신염의 치료를 위한 항-cd40 항체의 용도
AU2021272212A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
JP2025512032A (ja) Ｐｄ－１抗体を含有する安定した高濃度アルギニン製剤及びその使用方法
JP2025519612A (ja) Ｉｇｆ１ｒ抗体
KR20200044066A (ko) 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
WO2025098341A1 (en) IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
BR112018072125B1 (pt) Composição farmacêutica e seringa, injetor ou bomba
HK40102352A (en) Humanized anti-human-pd-1 antibody
JP2025512031A (ja) Ｐｄ－１抗体を含有する安定した高濃度塩化ナトリウム製剤及びその使用方法
JP2022524814A (ja) 抗ｌｉｎｇｏ－１抗体を含む医薬組成物
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK40018437A (en) Administration routes for immune agonists

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240229

Application number text: 1020227005469

Filing date: 20220217

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240422

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241024

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D